by EpiAxis | Jan 9, 2023 | News
EpiAxis Therapeutics, a leading LSD1 company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, is presenting at Biotech Showcase™ 2023. EpiAxis CEO Dr Jeremy Chrisp will discuss the company’s focus on...
by EpiAxis | Nov 7, 2022 | News
EpiAxis Therapeutics has signed a material transfer agreement (MTA) with Seattle Children’s Research Institute that will help researchers study a new approach to treating paediatric brain cancer. As part of the agreement, EpiAxis Therapeutics will supply its lead...
by EpiAxis | Oct 22, 2022 | News
EpiAxis Therapeutics CEO Dr Jeremy Chrisp this week joined Tech Tuesdays, a Canadian Securities Exchange virtual showcase that features in-depth discussions with companies shaking up the technology industry. The episode – Precision Medicine in Cancer Treatment...
by EpiAxis | Oct 5, 2022 | News
EpiAxis Therapeutics recently presented at BioPharm America 2022, part of Biotech Week Boston, giving investors an update on the company’s progress in the epigenetic space. BioPharm America is a conference where the new wave of life science innovators partner to...
by EpiAxis | Sep 12, 2022 | News
EpiAxis Therapeutics and University Health Network (UHN) – Canada’s largest and leading research hospital – have entered into a collaboration to study a new approach to prostate cancer treatment. As part of the agreement, EpiAxis Therapeutics will supply...
by EpiAxis | Aug 15, 2022 | News
EpiAxis Therapeutics and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a collaboration to...
